“South Korea’s Ilyang Pharmaceutical Co. hammered out a deal with Laboratorios Biopas S.A., a Colombian pharmaceutical company, to export Supect (radotinib), its new drug developed to cure leukemia, according to Ilyang on Monday.

The final agreement between the two companies comes almost a year after they signed an initial agreement in August last year, which allows Biopas, the 10th-largest drug maker in Colombia, to sell Supect. The deal also comes with licensing fees and certain milestone payments worth $22 million in total. ”
read more>>